ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa #genetherapy #clinicaltrial #ophthalmology #AAV
Info
ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. ViGeneron will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our ViGeneron technologies for additional indications.
- Website
-
https://vigeneron.com/
Externer Link zu ViGeneron GmbH
- Branche
- Biotechnologieforschung
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Planegg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2017
- Spezialgebiete
- Gene Therapy, Inherited Retinal Disorders und AAV vector
Orte
-
Primär
Wegbeschreibung
Semmelweisstr.
3
Planegg, 82152, DE
Beschäftigte von ViGeneron GmbH
Updates
-
Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron's REVeRT technology #AAV #genetherapy #innovation #ophthalmology
-
-
Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron's REVeRT technology #AAV #genetherapy #innovation #ophthalmology
-
ViGeneron announces EMA approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa #genetherapy #clinicaltrial #aav #ophthalmology